Members of both the American Society for Clinical Oncology and the Michigan Society of Hematology and Oncology are backing Senate Bill 625 (SB 625), which increases access to important oral chemotherapy treatments for cancer patients. Oral cancer drugs serve a critical role in the day-to-day care of cancer patients, yet many patients cannot afford their steep price tag. Co-pays for oral drugs may be thousands of dollars more than intravenous treatments. SB 625 ensures patient cost sharing policies are valid for both oral cancer drugs and traditional intravenous cancer drugs. Read more here.
Last Updated on May 8, 2020 by Aimed Alliance
